九福来
All categories

Milestone

Description:Dr. Zhang Rongxuan, a Chinese scientist of Jiangsu province, first introduced eight containers of aloe seedings of Aloe Vera from the Aloecorp base of America in Texas and planted it in Hainan Meiting Agricultural Development Experimental Zone.
Description:Dr. Zhang Rongxuan, a Chinese scientist of Jiangsu province, first introduced eight containers of aloe seedings of Aloe Vera from the Aloecorp base of America in Texas and planted it in Hainan Meiting Agricultural Development Experimental Zone.
Information

  On April 18,1999

Dr. Zhang Rongxuan, a Chinese scientist of Jiangsu province, first introduced eight containers of aloe seedings of Aloe Vera from the Aloecorp base of America in Texas and planted it in Hainan Meiting Agricultural Development Experimental Zone. Dr. Zhang Rongxuan named AloeVera as Curacao. Today, Aloe Vera has been a household name in China and Dr. Zhang has also been known as “Father of Aloe Vera in China” in aloe industry. At the same year in September, Zhang Rongxuan established China’s largest aloe vera planting base in Hainan province.

 

  In 2001

Hainan R&D center of Jufeel overcame the extract technology of aloe vera polysaccharide macromolecular carbohydrate and first introduced the concept of “aloe polysaccharide”.

 

  In May, 2002

Hainan R&D center of Jufeel was the first to put forward and realize the”six hours fresh-keeping, purification and processing for aloe vera" technique in China.

 

  In June, 2002

Hainan R&D center of Jufeel introduced an advanced aloe technology from the world's largest aloe raw material supplier, South Korean Nanyang Aloe Group Co., Ltd. and launched aloe vera compound ingredients, aloe tablets, the third generation rich in 5% of aloe polysaccharide retaining aloe vitamins, minerals, amino acids and active enzymes.

 

  In 2003

Professor Zhang Rongxuan used the technology of South Korean Nanyang Aloe Group Co., Ltd. and American Aloecorp to process the fourth generation aloe vera refined powder capsule, a separated live product rich in 10% of aloe polysaccharide.

 

  In 2004

Hainan R&D center of Jufeel started to explore the solution of renal failure and tumor diseases by using the fourth generation separated live product.

 

  In June, 2005

Hainan R&D center of Jufeel started to explore the solution of AIDS by using the fourth generation separated live product.

 

  In 2006

Professor Zhang Rongxuan began to cooperate with virus laboratory of the University of California, Davis, America and put forward the topic of building immune system of AIDS patients by using the fourth generation product.

 

  In 2007

Professor Zhang Rongxuan of Jufeel began to cooperate with scholars from Taiwan University and Taiwan Chung Shan Medical University, putting forward the topic of solving tumor problems and rebuilding immune system of AIDS patients by using the fourth-generation product.

 

  In June, 2008

Jufeel became the first company in China to use the technology of American Aloecorp to process aloe oral liquid, a kind of highly-absorbed separated live product rich in 25% of aloe polysaccharide; raw materials also evolved from original fluid to spray drying powder and freeze-dried powder, and to the fifth generation molecular sieve technology crystal drying powder.

 

  In September, 2010

Jufeel made the sixth generation injection products as new research topic and named them as Jufeel No.1, No.2, No.3 and No.4, seeking to improve the effect on human body with the fastest pace; and also took subdivision of aloe polysaccharide as a new research direction of Jufeel laboratory.

 

  In 2012

Jufeel cooperated with Life and Science School of Changzhou University to establish Jufeel natural drug R&D center and launched the sixth generation product. At the same time, Jufeel filed 10 invention patents to Chinese State Patent Office for the discovery of J-01, J-02 and J-031.

 

  In November, 2012

Taiwan joint scientific research team of Jufeel obtained ideal results in inhibiting AIDS virus and reconstructing immune recovery system by using aloe vera and mixed preparations of Chinese herbal medicine. J-01 and J-031 as independent R&D by Jufeel had good effect in virus inhibition and J-02 was mainly applied in reconstructing and improving immune system of human body.

 

  In 2013

Jufeel and College of Pharmacy of Nanjing University of Chinese Medicine conducted technical cooperation to jointly develop the latest drugs of aloe vera for anti-cancer, being young state and AIDS immune system reconstruction.

 

  In March, 2014

Jufeel announced that the being young state substance ZD-01 extracted from aloe vera increased by five to six times than the research data of 2013. This substance, known as super ZD cell energy element, was named PMAS by professor Zhang Rongxuan.

 

  In July, 2014

Jufeel officially announced that the most essential substance of aloe, PMAS, representing one of the highest international technical standards of aloe industry, was discovered and purified successfully after more than fifteen years of hard work, numerous experiments and continuous exploration.

 

  On May 20, 2016

Aloe polysaccharide oral liquid PMAS", a new AIDS adjuvant drug developed jointly by Jufeel biotechnology and Tanzania PMAS pharmaceutical company, was registered and approved by TFDA of Tanzania(Registered No.:TEN16FF0276). This is the first batch number of ancillary drug registration certificate obtained by "PMAS" aloe polysaccharide oral liquid in the east African community where AIDS is concentrated.

 

  On February 9, 2017

In Dar es Salaam, Tanzania, Jufeel Biotechnology donated aloe vera biologicals(PMAS) worthy $5.3 million to the National Institute of Health Research (NIMR) of the Ministry of Health of Tanzania. The signing ceremony held at the NIMR of the Ministry of Health of Tanzania. Jufeel and NIMR signed a three-year cooperative medical research agreement upon this donation ceremony. The research direction is to solve the problems of nephrology, oncology, and immune system deficiency, and is used for the development of public health cause in Tanzania.

 

  In July 2017

Jufeel Biotechnology donated “PMAS Aloe Oral Liquid”, worthy $5.3 million to the National Institute of Health Research (NIMR) of Tanzania, and it passed the global PONY test and the world's leading Swiss SGS test.

 

  In November 2017

At the International Summit on the 42nd Anniversary of the Establishment of Diplomatic Relations between China and Thailand and the “One Belt, One Road” Economic and Trade Culture Integrated Development Conference, Professor Zhang Rongxuan and Jufeel were respectively awarded the “One Belt and One Road Brand Star Special Contribution Award in Health Industry ” and “Black Technology Gold Award in Aloe Industry” .

 

  In December 2017

Professor Zhang Rongxuan was invited to the United States to participate in the United Nations "2030 Stop AIDS Spread" charity event, and was cordially received by US President Donald Trump. United Nations World AIDS Organization (WAOUN) presented Zhang Rongxuan with "World's Most Outstanding AIDS Prevention and Treatment Award". New York City Mayor Bill  de Blasio issued Mr. Zhang Rongxuan the New York Armband Medal, which fully affirmed his contribution to the AIDS public welfare undertaking.

 

  In April 2018

Professor Zhang Rongxuan brought “the role of "PMAS" in the recovery and regeneration of brain neurons and new techniques of senile dementia and brain atrophy", together with Dr. Yan Weijun,a distinguished professor of Zhejiang University, medical expert of Thousand Talents Program in Zhejiang province, who won the English Medicine Award, participated in the 46th Geneva International Invention Exhibition and won the gold medal in the category of “Medical Health” .

On May 31, 2018, the invention patent on the "method for the use of aloe vera to prepare freeze-dried powder injection for promoting estrogen secretion" received the official approval letter from the examiner of United States Patent and Trademark Office, application number: US15/011450, international PCT invention patent number: PCT/CN2013/001297 10/282013, marking the world's cutting-edge biotechnology through aloe vera extract to achieve anti-aging and youthful state.

 

  On August 30, 2018

Special subject research on the effect of PMAS aloe film on the clinical symptoms of women with menopausal syndrome was launched in the General Hospital of the People's Liberation Army (301 Hospital).

 

  In September, 2018

At the 20th Special Seminar on International Safety of AIDS and Infectious Diseases, the President of the General Assembly, Mr. Rex Stoton, personally issued the academic honor certificate to professor Zhang Rongxuan, jointly awarded by the world's three prestigious universities, Oxford University, University of Strasbourg, France, and University of California, United States.

 

  On September 12, 2018

Mr. IGOGO, Special Economic Advisor of the President of Tanzania, specially came to China to thank professor Zhang Rongxuan, the international patent holder of PMAS technology and Chairman of the Board of Directors of Jufeel International Group, and brought the clinical reports of several hospitals in Tanzania. In first phase clinical trials, 36 people had AIDS. After three months of PMAS combined with antiretroviral drugs, the blood HIV load decreased by an average of 89%, and 7 of them had an HIV load of 0. The results of PMAS treatment of AIDS far exceed the expectations of the Tanzanian side, and Tanzania is very grateful to professor Zhang Rongxuan for his contribution to the country's public health cause.

 

  In March 2019

Jufeel donated PMAS biologicals worthy more than $5 million to the National Institute of Health Research (NIMR) of the Ministry of Health of Tanzania for the second phase clinical trial of AIDS. The second phase of clinical involves 600 patients, the research cycle is 6 months, and it is expected that the upgrading from auxiliary drugs to conventional drugs will be completed before December 2019, and enter the Tanzanian medical insurance system.

 

  In March 2019

Jufeel and Zhejiang University signed a cooperation agreement on the development of the new type natural polysaccharide compound PMAS as new drug anti-HIV. Joint efforts by schools and enterprises can provide new pharmaceuticals and treatment strategies to solve public health problems in the world.

 

  On March 29, 2019

The S-1 filing of Jufeel International Group (code: CNJG) to the US Securities and Exchange Commission (SEC) finally came into effect after several rounds of review by SEC.

Scan the QR code to read on your phone